Literature DB >> 34088304

Downregulation of exosomal let-7d and miR-16 in idiopathic pulmonary fibrosis.

Donato Lacedonia1,2, Giulia Scioscia3,4, Piera Soccio3,4, Massimo Conese3, Lucia Catucci5, Grazia P Palladino6, Filomena Simone3, Carla M I Quarato3, Sante Di Gioia3, Roberto Rana3, Francesco Sollitto7, Maria P Foschino-Barbaro3,4.   

Abstract

BACKGROUND: Idiopathic Pulmonary Fibrosis (IPF) is a degenerative interstitial lung disease with both a poor prognosis and quality of life once the diagnosis is made. In the last decade many features of the disease have been investigated to better understand the pathological steps that lead to the onset of the disease and, moreover, different types of biomarkers have been tested to find valid diagnostic, prognostic and therapy response predictive ones. In the complexity of IPF, microRNA (miRNAs) biomarker investigation seems to be promising.
METHODS: We analysed the expression of five exosomal miRNAs supposed to have a role in the pathogenesis of the disease from serum of a group of IPF patients (n = 61) and we compared it with the expression of the same miRNAs in a group of healthy controls (n = 15).
RESULTS: In the current study what emerged is let-7d down-regulation and, unexpectedly, miR-16 significant down-regulation. Moreover, through a cross-sectional analysis, a clustering of the expression of miR-16, miR-21 and miR-26a was found.
CONCLUSIONS: These findings could help the individuation of previously unknown key players in the pathophysiology of IPF and, most interestingly, more specific targets for the development of effective medications.

Entities:  

Keywords:  Biomarkers; Exosomes; Idiopathic pulmonary fibrosis; microRNA

Year:  2021        PMID: 34088304     DOI: 10.1186/s12890-021-01550-2

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  25 in total

1.  [Drug-induced interstitial lung disease].

Authors:  Akihiko Gemma
Journal:  Gan To Kagaku Ryoho       Date:  2008-10

2.  miR-210 promotes IPF fibroblast proliferation in response to hypoxia.

Authors:  Vidya Bodempudi; Polla Hergert; Karen Smith; Hong Xia; Jeremy Herrera; Mark Peterson; Wajahat Khalil; Judy Kahm; Peter B Bitterman; Craig A Henke
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

3.  Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.

Authors:  K B Baumgartner; J M Samet; C A Stidley; T V Colby; J A Waldron
Journal:  Am J Respir Crit Care Med       Date:  1997-01       Impact factor: 21.405

4.  Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells.

Authors:  Yan-Ni Xi; Xiao-Yan Xin; Hong-Mei Ye
Journal:  Asian Pac J Trop Med       Date:  2014-04       Impact factor: 1.226

5.  miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF.

Authors:  Haihai Liang; Shanshan Liu; Yang Chen; Xue Bai; Li Liu; Yuechao Dong; Meiyu Hu; Xiaomin Su; Yingzhun Chen; Longtao Huangfu; Xuelian Li; Yunyan Gu; Hongli Shan
Journal:  J Mol Med (Berl)       Date:  2016-01-20       Impact factor: 4.599

6.  Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.

Authors:  Margaret L Salisbury; Meng Xia; Yueren Zhou; Susan Murray; Nabihah Tayob; Kevin K Brown; Athol U Wells; Shelley L Schmidt; Fernando J Martinez; Kevin R Flaherty
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

Review 7.  MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics.

Authors:  Huimin Li; Xiaoguang Zhao; Hongli Shan; Haihai Liang
Journal:  Acta Pharm Sin B       Date:  2016-07-27       Impact factor: 11.413

8.  The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Authors:  Andreas Guenther; Ekaterina Krauss; Silke Tello; Jasmin Wagner; Bettina Paul; Stefan Kuhn; Olga Maurer; Sabine Heinemann; Ulrich Costabel; María Asunción Nieto Barbero; Veronika Müller; Philippe Bonniaud; Carlo Vancheri; Athol Wells; Martina Vasakova; Alberto Pesci; Matteo Sofia; Walter Klepetko; Werner Seeger; Fotios Drakopanagiotakis; Bruno Crestani
Journal:  Respir Res       Date:  2018-07-28

9.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

Review 10.  Epidemiology of idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard
Journal:  Clin Epidemiol       Date:  2013-11-25       Impact factor: 4.790

View more
  4 in total

Review 1.  Current and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review).

Authors:  Tao Yang; Jian Wang; Jiaying Zhao; Yang Liu
Journal:  Int J Mol Med       Date:  2022-01-28       Impact factor: 4.101

Review 2.  Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis.

Authors:  Yang Yang; Yufei Liu; Yilu Chai; Ke Liu; Wei Hu; Keni Zhao; Yi Zhu; Peiyang Gao; Qingsong Huang; Chuantao Zhang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 3.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 4.  Exosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis.

Authors:  María Cristina Negrete-García; Javier de Jesús Ramos-Abundis; Noé Alvarado-Vasquez; Eduardo Montes-Martínez; Martha Montaño; Carlos Ramos; Bettina Sommer
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.